J
Jeffrey J. Legos
Researcher at Novartis
Publications - 40
Citations - 5414
Jeffrey J. Legos is an academic researcher from Novartis. The author has contributed to research in topics: Dabrafenib & Trametinib. The author has an hindex of 24, co-authored 39 publications receiving 4571 citations. Previous affiliations of Jeffrey J. Legos include Temple University & GlaxoSmithKline.
Papers
More filters
Journal ArticleDOI
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Georgina V. Long,Georgina V. Long,Daniil Stroyakovskiy,Helen Gogas,Evgeny Levchenko,Filippo de Braud,James Larkin,Claus Garbe,Thomas Jouary,Axel Hauschild,Jean-Jacques Grob,Vanna Chiarion-Sileni,Céleste Lebbé,Mario Mandalà,Michael Millward,Ana Arance,Igor Bondarenko,John B. A. G. Haanen,Johan Hansson,Jochen Utikal,Jochen Utikal,Virginia Ferraresi,Nadezhda Kovalenko,Peter Mohr,Volodymr Probachai,Dirk Schadendorf,Paul Nathan,Caroline Robert,Caroline Robert,Antoni Ribas,Douglas J Demarini,Jhangir G. Irani,Suzanne Swann,Jeffrey J. Legos,Fan Jin,Bijoyesh Mookerjee,Keith T. Flaherty +36 more
TL;DR: The improvement in overall survival establishes the combination of dabrafenib and trametinib as the standard targeted treatment for BRAF Val600 mutation-positive melanoma.
Journal ArticleDOI
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
Georgina V. Long,A. Hauschild,M. Santinami,Victoria Atkinson,M. Mandal,Vanna Chiarion-Sileni,James Larkin,Marta Nyakas,Caroline Dutriaux,Andrew Haydon,Caroline Robert,Laurent Mortier,Jacob Schachter,Dirk Schadendorf,Thierry Lesimple,Ruth Plummer,R. Ji,Ping Zhang,Bijoyesh Mookerjee,Jeffrey J. Legos,Richard F. Kefford,Reinhard Dummer,John M. Kirkwood +22 more
TL;DR: Adjuvant use of combination therapy with dabrafenib plus trametinib resulted in a significantly lower risk of recurrence in patients with stage III melanoma with BRAF V600E or V600K mutations than the adjuvantUse of placebo and was not associated with new toxic effects.
Journal ArticleDOI
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
Georgina V. Long,Keith T. Flaherty,Daniil Stroyakovskiy,Helen Gogas,Evgeny Levchenko,F. de Braud,James Larkin,Claus Garbe,Thomas Jouary,Axel Hauschild,Vanna Chiarion-Sileni,Céleste Lebbé,Mario Mandalà,Michael Millward,Ana Arance,Igor Bondarenko,J.B.A.G. Haanen,Johan Hansson,Jochen Utikal,Virginia Ferraresi,Peter Mohr,V. Probachai,Dirk Schadendorf,Paul Nathan,Caroline Robert,Antoni Ribas,Michael A. Davies,Stephen R. Lane,Jeffrey J. Legos,Bijoyesh Mookerjee,J.-J. Grob +30 more
TL;DR: It is demonstrated that durable (≥3 years) survival is achievable with dabrafenib plus trametinib in patients with BRAF V600-mutant metastatic melanoma and support long-term first-line use of the combination in this setting.
Journal ArticleDOI
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis
Jennifer L. McQuade,Carrie R. Daniel,Kenneth R. Hess,Carmen Mak,Daniel Y. Wang,Rajat Rai,John J. Park,Lauren E. Haydu,Christine N. Spencer,Matthew Wongchenko,Stephen R. Lane,Dung Yang Lee,Mathilde Kaper,Meredith Ann McKean,Kathryn E. Beckermann,Samuel M. Rubinstein,Isabelle Rooney,Luna Musib,Nageshwar Budha,Jessie Hao-Ru Hsu,Theodore S. Nowicki,Alexandre Avila,Tomas Haas,Maneka Puligandla,Sandra J. Lee,Shenying Fang,Jennifer A. Wargo,Jeffrey E. Gershenwald,Jeffrey E. Lee,Patrick Hwu,Paul B. Chapman,Jeffrey A. Sosman,Dirk Schadendorf,Jean-Jacques Grob,Keith T. Flaherty,Dana Walker,Yibing Yan,Edward McKenna,Jeffrey J. Legos,Matteo S. Carlino,Matteo S. Carlino,Antoni Ribas,John M. Kirkwood,Georgina V. Long,Douglas B. Johnson,Alexander M. Menzies,Michael A. Davies +46 more
TL;DR: In patients with metastatic melanoma, obesity is associated with improved progression-free survival and overall survival compared with those outcomes in patients with normal BMI, and that this association is mainly seen in male patients treated with targeted or immune therapy.
Journal ArticleDOI
Caspase 3 activation is essential for neuroprotection in preconditioning.
BethAnn McLaughlin,Karen A. Hartnett,Joseph A. Erhardt,Jeffrey J. Legos,Raymond F. White,Frank C. Barone,Elias Aizenman +6 more
TL;DR: A neuroprotective pathway where events normally associated with apoptotic cell death are critical for cell survival is outlined, and agents that blocked preconditioning also attenuated induction of HSP 70.